Literature DB >> 35254566

Experimental laboratory biomarkers in multiple sclerosis.

Borros Arneth1, Jörg Kraus2,3.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system; the cause of this condition remains unknown. Researchers have analyzed different biomarkers related to MS. Here, experimental laboratory biomarkers for MS are identified and analyzed.
METHODS: The current study examined articles investigating biomarkers for MS. Records were obtained from the PubMed, LILACS, and EBSCO databases using an identical search strategy and terms that included "multiple sclerosis," "MS," and "biomarkers." In the current review, we also focus on lesser known biomarkers that have not yet been established for use in clinical practice.
RESULTS: Previous studies have explored molecular substances that may help diagnose MS and manage its adverse effects. Commonly studied factors include neurofilaments, sCD163, CXCL13, NEO, NF‑L, OPN, B cells, T cells, and integrin-binding proteins.
CONCLUSIONS: Interactions between environmental and genetic factors have been implicated in the development of MS. Previous investigations have identified a wide range of biomarkers that can be used for diagnosis and disease management. These molecules and their associated studies provide vital insight and data to help primary physicians improve clinical and health outcomes for MS patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, ein Teil von Springer Nature.

Entities:  

Keywords:  Biomarkers; Biomarkers in multiple sclerosis; Development; Disease activity; Progression

Year:  2022        PMID: 35254566     DOI: 10.1007/s10354-022-00920-7

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  71 in total

1.  Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.

Authors:  Eduardo Beltrán; Birgit Obermeier; Markus Moser; Francisco Coret; María Simó-Castelló; Isabel Boscá; Francisco Pérez-Miralles; Luisa M Villar; Makbule Senel; Hayrettin Tumani; Reinhard Hohlfeld; Bonaventura Casanova; Klaus Dornmair
Journal:  Brain       Date:  2014-07-23       Impact factor: 13.501

2.  Time to first relapse as an endpoint in multiple sclerosis clinical trials.

Authors:  M P Sormani; A Signori; P Siri; N De Stefano
Journal:  Mult Scler       Date:  2012-08-22       Impact factor: 6.312

3.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

4.  Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants.

Authors:  Kevin Blauth; John Soltys; Adeline Matschulat; Cory R Reiter; Alanna Ritchie; Nicholas L Baird; Jeffrey L Bennett; Gregory P Owens
Journal:  Acta Neuropathol       Date:  2015-10-28       Impact factor: 17.088

5.  Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Authors:  Amit Bar-Or; Lama Fawaz; Boli Fan; Peter J Darlington; Aja Rieger; Christine Ghorayeb; Peter A Calabresi; Emmanuelle Waubant; Stephen L Hauser; Jiameng Zhang; Craig H Smith
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 6.  Humoral autoimmunity in multiple sclerosis.

Authors:  Edgar Meinl; Tobias Derfuss; Markus Krumbholz; Anne-Katrin Pröbstel; Reinhard Hohlfeld
Journal:  J Neurol Sci       Date:  2010-09-03       Impact factor: 3.181

7.  Inflammatory cortical demyelination in early multiple sclerosis.

Authors:  Claudia F Lucchinetti; Bogdan F G Popescu; Reem F Bunyan; Natalia M Moll; Shanu F Roemer; Hans Lassmann; Wolfgang Brück; Joseph E Parisi; Bernd W Scheithauer; Caterina Giannini; Stephen D Weigand; Jay Mandrekar; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

8.  The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Authors:  Antonio Scalfari; Anneke Neuhaus; Alexandra Degenhardt; George P Rice; Paolo A Muraro; Martin Daumer; George C Ebers
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

9.  B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Authors:  Sara A J Thompson; Joanne L Jones; Amanda L Cox; D Alastair S Compston; Alasdair J Coles
Journal:  J Clin Immunol       Date:  2009-09-10       Impact factor: 8.317

10.  Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.

Authors:  Tobias Derfuss; Khyati Parikh; Sviataslau Velhin; Magdalena Braun; Emily Mathey; Markus Krumbholz; Tania Kümpfel; Anja Moldenhauer; Christoph Rader; Peter Sonderegger; Walter Pöllmann; Christian Tiefenthaller; Jan Bauer; Hans Lassmann; Hartmut Wekerle; Domna Karagogeos; Reinhard Hohlfeld; Christopher Linington; Edgar Meinl
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.